Background Afghanistan's national guidelines recommend chloroquine for the treatment of
Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden …

Background. Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax
malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ …

Background Chloroquine has been recommended for Plasmodium vivax infections for> 60
years, but resistance is increasing. To guide future therapies, the cumulative benefits of …

Abstract Background. Chloroquine (CQ)-resistant Plasmodium vivax is increasingly reported
throughout southeast Asia. The efficacy of CQ and alternative artemisinin combination …

Background Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but
there is evidence for its declining efficacy. Defining the extent and regional distribution of CQ …

Background This study aimed to synthesize available evidence on the efficacy of
dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria …

Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is,
however, little information on P. vivax resistance to chloroquine and chloroquine plus …

Chloroquine (CQ) is a relatively inexpensive drug for treatment of malaria. If efficacy of CQ is
still assumed, then it should be indicated in malaria treatment policies as the drug of choice …

ABSTRACT Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for
radical cure of Plasmodium vivax malaria. Emergence of CQ-resistant (CQR) P. vivax …

Background Chloroquine is the first-line treatment for Plasmodium vivax malaria in most
endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is …